One-Year Outcomes of Heparin-Bonded Stent-Graft Therapy for Real-World Femoropopliteal Lesions and the Association of Patency With the Prothrombotic State Based on the Prospective,Observational,Multicenter V i a bahn Ste n t-Graft Placement for Femoropopliteal Diseases Re qui ring Endova s cular T h erapy (VANQUISH) Study

Abstract

Purpose:

To evaluate the real-world primary patency of heparin-bonded stent-graft therapy for femoropopliteal (FP) occlusive disease and identify any clinical factors, including the prothrombotic state, associated with the loss of patency.

Materials and Methods:

This multicenter study prospectively enrolled 424 limbs of 371 patients (mean age 75±8 years; 247 men) scheduled for Viabahn stent-graft placement in the FP segment. A full-coverage strategy using only a Viabahn stent-graft was preferred, but “spot stenting” with the Viabahn was also allowed. The prothrombotic state was assessed by measuring platelet reactivity. Vascular morphology was evaluated using intravascular ultrasound (IVUS). Primary patency was estimated using the Kaplan-Meier method in the subgroup of patients having full lesion stent-graft coverage (n=343 limbs, 81.1%). The secondary outcomes were major amputation, surgical reconstruction, target lesion revascularization (TLR), and thrombotic occlusion. Regression analyses were used to explore associations of baseline and clinical variables with loss of patency; the results are given as the odds ratio (OR) and 95% confidence interval (CI).

Results:

The 1-year primary patency estimate was 80.3% (95% CI 75.5% to 85.1%) in the full-coverage group. There were 7 surgical reconstructions, 46 TLRs, 21 acute thrombotic occlusions, and 1 major amputation during the 1-year follow-up in the full-coverage group. Only angiography- and IVUS-determined vessel diameters were significantly associated with loss of patency, with crude ORs of 0.64 (95% CI 0.45 to 0.89, p=0.009) and 0.67 (95% CI 0.51 to 0.90, p=0.009), respectively, per 1-mm increase, whereas other variables, including the prothrombotic state (p=0.74), were not. Multivariable analysis demonstrated that only IVUS-determined vessel diameter was independently associated with loss of patency (adjusted OR per 1-mm increase 0.72, 95% CI 0.52 to 1.00, p=0.049).

Conclusion:

FP stent-graft placement achieved acceptable patency at 1 year in a real-world setting. A smaller vessel size was significantly associated with loss of patency, whereas the prothrombotic state was not.

Keywords

antiplatelet therapy covered stent endoluminal bypass endovascular treatment/therapy femoropopliteal segment intravascular ultrasound imaging patency platelet reactivity stent-graft thrombotic occlusion vessel diameter

Get full access to this article

View all access options for this article.

References

Ohki

Kichikawa

Yokoi

, et al. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg. 2017;66:130–42.e1.

Lammer

Zeller

Hausegger

, et al. Heparin-bonded covered stents versus bare metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial. J Am Coll Cardiol. 2013;62:1320–1327.

Reijnen

MMPJ

van Walraven

Fritschy

, et al. 1-Year results of a multicenter randomized controlled trial comparing heparin bonded endoluminal to femoropopliteal bypass. JACC Cardiovasc Interv. 2017;10:2320–2331.

Aboyans

Ricco

Bartelink

MEL

, et al; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.

Dake

Ansel

Jaff

, et al; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.

Soga

Iida

Hirano

, et al. Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg. 2011;54:1058–1066.

Iida

Urasawa

Komura

, et al. Self-expanding nitinol stent vs percutaneous transluminal angioplasty in the treatment of femoropopliteal lesions: 3-year data from the SM-01 trial. J Endovasc Ther. 2019;26:158–167.

Iida

Takahara

Soga

, et al; ZEPHYR Investigators. 1-Year results of the ZEPHYR registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv. 2015;8:1105–1112.

Banerjee

Sarode

Mohammad

, et al. Femoropopliteal artery stent thrombosis: report from the excellence in peripheral artery disease (XLPAD) registry. Circ Cardiovasc Interv. 2016;9:e002730.

10.

Bradaric

Koppara

Müller

, et al. Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery. EuroIntervention. 2019; 15:e1107–e1114.

11.

Stone

Witzenbichler

Weisz

, et al; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013; 382:614–623.

12.

Valgimigli

Bueno

Byrne

, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–260.

13.

Rocha-Singh

Zeller

Jaff

MR.

Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212–E220.

14.

Ranke

Creutzig

Alexander

Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18:433–440.

15.

Hiramori

Soga

Iida

, et al. Relationship between clinical outcomes and vessel size in endovascular therapy for femoropopliteal lesions. J Vasc Surg. 2017;65:1690–1697.

16.

Mintz

Nissen

Anderson

, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37: 1478–1492.

17.

Saxon

Chervu

Jones

, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013;24: 165–173.

18.

Ishihara

Iida

Inoue

, et al. Histological evaluation of a self-expanding stent graft 23 months after implantation in the superficial femoral artery. J Endovasc Ther. 2017;2:746–750.

19.

Bonaca

Bauersachs

Anand

, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994–2004.